Why did the Race Oncology (ASX:RAC) share price drop 10% today?

What happened with Race shares today?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The Race Oncology share price slipped almost 10% today
  • It hit a new 12 month low during intraday trading 
  • Today's fall has dragged Race shares more than 36% lower in 2022 so far

Today wasn't a great day for most ASX shares. The All Ordinaries Index (ASX: XAO) ended up losing 0.93% over this Tuesday's trading session. But that loss was eclipsed by the Race Oncology Ltd (ASX: RAC) share price.

Race shares ended up finishing at $2.30 a share, down a nasty 9.8% for the day. What's worse, the company hit $2.27 during intra-day trading a new 52-week low for Race Oncology. That puts the company's losses over 2022 so far at 36%, including 17.3% over the past 5 trading days. Its 12-month loss now stands at 38%.

So why did this company have such a lousy day of trading today?

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.

Image source: Getty Images

Race to the bottom for Race Oncology share price

Well, unfortunately, it's not entirely clear. There were no announcements or news out of the company to speak of. Nor have there been since a major update in January, which was an activities update for the December quarter. Back then, the company announced that its capital raising had been successful and oversubscribed at $3 a share. Race also reported a healthy cash position as well as a "preclinical discovery into heart protection during cancer treatment".

That caused the Race share price to rise at the time. But investors appear to have forgotten all about those developments today.

So while it's unclear exactly what spooked investors today, it could just be the nature of the company itself. As a small-cap ASX share with a market capitalisation of just over $400 million, Race is a company that could have been treated as a more speculative investment by some of its shareholders. As such, on a day like today when investors didn't seem in the mood to take risks, Race shares might have just been the victim of some fear-provoked selling pressure.

Whatever the reasons for today's sell off, Race shareholders will undoubtedly be hoping for better fortunes over the rest of the week.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX small-cap healthcare stock could rocket more than 50%: Morgans

Share price weakness could present an opportunity.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Guess which ASX 300 stock was given a big boost from the US FDA

This healthcare stock has made a positive announcement today.

Read more »

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Broker Notes

Down 43% this week, are Cochlear shares now the best bargain buy of the year?

A leading analyst believes the historic selloff in Cochlear shares could present a unique buying opportunity.

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Down 50%, why I'd invest $20,000 into CSL shares

A 50% decline in a blue-chip share can signal trouble, but not always a broken story.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech stock could deliver 40%-plus returns Morgans says

This small company continues to kick goals.

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Healthcare Shares

How high could Cochlear shares bounce back? Brokers disagree

Despite bad news on the earnings front this week, Cochlear shares could still deliver upside.

Read more »

Retired couple hugging and laughing.
Healthcare Shares

A Budget announcement has put a rocket under this ASX aged care provider's shares

A shake up in the funding model will be a boost for this company.

Read more »

An arrow crashes through the ground as a businessman watches on.
Healthcare Shares

Cochlear stock down 40%: How much has this cost ASX investors?

One day can ruin years of success...

Read more »